Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

Core Viewpoint - Dynavax Technologies Corporation emphasizes the importance of voting for its director nominees and criticizes Deep Track's plan as detrimental to stockholder value [2][3]. Group 1: Company Performance - Dynavax has achieved a total return of 203% for stockholders over the last five years, significantly outperforming vaccine peers (9% return) and the S&P Biotechnology Select Industry Index (-17% return) [4]. - The company reported $268 million in net product revenue from HEPLISAV-B® in 2024, capturing approximately 44% of the U.S. market share by year-end [4]. - In Q1 2025, Dynavax recorded net product revenue of $65 million from HEPLISAV-B®, marking a 36% year-over-year increase, with total revenue reaching $68.2 million, a 34% increase year-over-year [4]. - From 2020 to 2022, Dynavax generated over $950 million in net product revenue through its business development strategy during the pandemic [4]. Group 2: Board and Governance - The Dynavax Board of Directors unanimously recommends stockholders vote "FOR" all four director nominees, highlighting their qualifications and strategic leadership [3][4]. - The Board has implemented a proactive refreshment plan, with six of the eight independent directors appointed since 2020, enhancing accountability and oversight [4]. - Dynavax's capital allocation strategy includes a $200 million share repurchase program, of which over 85% has been executed, representing 47% of the company's capital use [4]. Group 3: Competitive Landscape - Deep Track's plan is criticized for being myopic, focusing solely on monetizing HEPLISAV-B® for immediate capital return, which could jeopardize Dynavax's long-term growth opportunities [4]. - Deep Track rejected reasonable settlement proposals, insisting on direct Board representation and a flawed strategy that would undermine Dynavax's expertise [4].